Ponatinib plus asciminib in myeloid blast-phase CML harboring a phased BCR::ABL1 Y253H/T315I compound mutation: a case report
A heavily pretreated patient with myeloid blast-phase CML in whom next-generation sequencing at blast transformation identified Y253H, T315I, and a low-level Y253_E255delinsHGK variant is reported, and phasing analysis demonstrated that Y253H and T315I were present on the same BCR::ABL1 allele, confirming a true compou...